Innovative Therapeutics Aqualung Therapeutics is focused on developing novel anti-inflammatory monoclonal antibodies targeting NAMPT to treat severe lung conditions such as VILI, idiopathic pulmonary fibrosis, and pulmonary hypertension, presenting opportunities for partnerships or licensing in advanced biotech pipelines.

Recent Funding & Recognition With a recent $2.5 million investment and industry awards like the AZ Bio Fastlane Award, the company is gaining credibility and momentum, indicating potential for investor interest and strategic collaborations to accelerate drug development and commercialization efforts.

Research Focus Areas Aqualung's emphasis on unmet needs in life-threatening inflammatory conditions offers sales opportunities in clinical trial partnerships, research collaborations, and supplying innovative antibody platforms to biotech and pharmaceutical companies targeting similar indications.

Leadership Expansion The addition of new board members such as Dr. Jackson Streeter signals strategic growth and heightened industry engagement, creating prospects to explore executive-level partnerships, consultative sales, or collaborative ventures in biotech innovation.

Market Positioning As an early-stage biotech with a proprietary platform and strong research awards, Aqualung presents potential sales channels in specialist biotech and research institutions, as well as early adoption opportunities for advanced therapeutic platforms in inflammatory and lung disease markets.